Vaccine makers targeting COVID-19 to measles will come under investor scrutiny on Tuesday as a group of independent experts at the CDC are scheduled to meet for the first time to review U.S.

Novavax, Inc. (Nasdaq: NVAX) today announced preliminary results from the SHIELD-Utah study (Study of Healthcare Workers and First Responders Investigating Effects of Systemic and Local reactogenicity ...

Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services ...

Shares of Novavax NVAX were down 19.6% on April 10 after the United States Health and Human Services (“HHS”) Secretary Robert ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Shares of Novavax Inc. NVAX tumbled 19.56% to $5.43 Thursday, on what proved to be an all-around dismal trading session for ...

Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

In an emailed statement to The Fly, Novavax (NVAX) said, “As we have previously stated, we believe that our Biologics License Application for ...

BofA lowered the firm’s price target on Novavax (NVAX) to $10 from $12 and keeps a Neutral rating on the shares. Shares are sliding over 21% ...

Novavax (NASDAQ: NASDAQ:NVAX) stock plummeted 24% after comments from Health and Human Services Secretary Robert F. Kennedy Jr. suggested a shift in government priorities away from the company’s ...

Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board ...